After the patent falls, the real fight begins.
Most people think the end of a patent is the end of the story. In pharma, it’s the opening scene of a new one—where timing, regulatory strategy, and litigation posture determine whether generics arrive s…

AI is your drug’s new KOL—and you’re not tracking it.
For years, pharma has treated “influence” like a human problem: key opinion leaders, advisory boards, conference circuits, and the quiet gravity of a respected clinician’s citation trail. But the ce…

Most pharma companies don’t miss the patent—they miss the money.
Patent expiry is treated like a cliff. But for many brands, it’s more like a slow leak: value drains long before the last day on the calendar—through licensing, carve-outs, and “quiet” de…

Drug patent strategy is often treated like a calendar exercise—until it isn’t.
The industry knows the headlines: “Patent expiry,” “generic entry,” “launch timing.” But portfolio planning fails most often at the exact moment teams assume the date is a s…

Can I Take Lipitor and Pain Relievers Before Bedtime? A Comprehensive Guide Taking medications before bedtime can be a common… https://www.Drugchatter.com/chat/21744/can-i-take-lipitor-and-pain-relievers-before-bedtime/

Generic entry is inevitable. The question is: who’s prepared for it?
Most people in pharma talk about patents like they’re shields—clean, obvious, and easy to understand. But the real battlefield is often less visible: the manufacturing process itself….

Biotech investing can feel like a high-wire act—until you realize the wire is made of patents.
In the rush to underwrite growth, investors often focus on pipeline quality, trial design, and cash runway. But one risk category quietly determines whether …

Biosimilar entry windows aren’t just math—they’re strategy under uncertainty.
The industry has gotten very good at building models. But the most expensive outcomes often come from the same place: companies treat those models like forecasts instead of…

Generic & biosimilar development is a high-stakes chess match—your first move should be a patent landscape.
Most teams treat patent work like a compliance checkbox: “We’ll check the patents later.” But in generic and biosimilar development, “later”…

Designing Around the Moat: How Generic Developers Can Navigate Secondary Formulation Patents
In generic drug development, the real fight often isn’t the active ingredient—it’s the moat around it.
For years, the industry’s attention has been fixed on pr…